74 results
10-K
2019 FY
EX-10.13
ORTX
Orchard Therapeutics plc
27 Feb 20
Annual report
4:02pm
which to exercise the Share Option may be subject to earlier termination as set forth below.
(a)Termination Due to Death. If the Optionee’s employment … terminates by reason of the Optionee’s death, any portion of this Share Option outstanding on such date, to the extent exercisable on the date
DRS
EX-10.2
ORTX
Orchard Therapeutics plc
6 Aug 18
Draft registration statement
12:00am
at the date of death) during the period ending 12 months after his death.
An Option Holder who gives or receives notice of termination of employment … the transmission of an Option to an Option Holder’s personal representatives on the death of the Option Holder.
An Option shall lapse
F-1
EX-10.2
ORTX
Orchard Therapeutics plc
4 Oct 18
Registration statement (foreign)
4:48pm
of death) during the period ending 12 months after his death.
An Option Holder who gives or receives notice of termination of employment or who … the transmission of an Option to an Option Holder’s personal representatives on the death of the Option Holder.
An Option shall lapse on the earliest
S-8
EX-99.2
ORTX
Orchard Therapeutics plc
6 Aug 20
Registration of securities for employees
4:07pm
death. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws … any Award or receive any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided
10-K
2019 FY
EX-10.16
ORTX
Orchard Therapeutics plc
27 Feb 20
Annual report
4:02pm
notice to you.
Death in Service Benefit
The Company operates a Death in Service Scheme. Membership of the Death in Service Scheme is dependent upon … .
The Company reserves the right to withdraw or amend the Death in Service Scheme (including the level of cover provided under the Scheme) at any time
F-1/A
EX-3.1
wv4 1nirzwpxvn
23 Oct 18
Registration statement (foreign) (amended)
6:15am
20-F
EX-1.1
70w3ns7bqv0tunpt53jo
22 Mar 19
Annual report (foreign)
8:02am
10-Q
EX-10.1
7kjkouyna97n
7 May 20
Quarterly report
4:03pm
10-K
EX-10.15
p7djc h9x6ctn11
27 Feb 20
Annual report
4:02pm
8-K
EX-3.1
zamj7 uj6tz
19 Jun 20
Amendments to Articles of Incorporation or Bylaws
4:09pm
8-K
EX-10.1
jydh 1ys4rx23
6 Oct 22
Entry into a Material Definitive Agreement
4:34pm
6-K
EX-99.1
wu466jyn55po v1mvu
6 Nov 19
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
4:07pm
10-K
EX-10.14
xxsm9izf
27 Feb 20
Annual report
4:02pm
8-K
EX-99.1
zmvlmit
23 May 23
Regulation FD Disclosure
7:06am
6-K
EX-99.1
idqyea9g5to7z6540lx4
25 Apr 19
Program on Track for MAA and BLA Regulatory Submissions in 2021
4:00pm
6-K
EX-99.1
91n6t71f1f
30 Jul 19
Three-Year Registrational Data Set to be Presented by Year End 2019
4:00pm
F-1/A
EX-10.3
qotvccbl9sp15vvv8w
23 Oct 18
Registration statement (foreign) (amended)
6:15am
20-F
EX-4.3
6spp5e
22 Mar 19
Annual report (foreign)
8:02am
6-K
EX-99.1
2zdxzhi8f8oef
25 Feb 19
Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID
12:00am
8-K
EX-99.1
qji gtm67ynsld
26 Oct 23
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
4:35pm